MEP27508A - N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris - Google Patents
N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectorisInfo
- Publication number
- MEP27508A MEP27508A MEP27508A MEP27508A ME P27508 A MEP27508 A ME P27508A ME P27508 A MEP27508 A ME P27508A ME P27508 A MEP27508 A ME P27508A
- Authority
- ME
- Montenegro
- Prior art keywords
- infarction
- treatment
- angina pectoris
- oxo2
- nhe
- Prior art date
Links
- 206010061216 Infarction Diseases 0.000 title abstract 3
- 230000007574 infarction Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- MGRUNSIBUNAFKA-UHFFFAOYSA-N n-(diaminomethylidene)-2-(3-oxo-1,2-dihydroisoindol-1-yl)acetamide Chemical class C1=CC=C2C(CC(=O)NC(=N)N)NC(=O)C2=C1 MGRUNSIBUNAFKA-UHFFFAOYSA-N 0.000 title 1
- 208000028867 ischemia Diseases 0.000 abstract 2
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000003293 cardioprotective effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035778 pathophysiological process Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0206783A FR2840302B1 (fr) | 2002-06-03 | 2002-06-03 | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| PCT/EP2003/005279 WO2003101450A1 (en) | 2002-06-03 | 2003-05-20 | N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP27508A true MEP27508A (en) | 2010-06-10 |
Family
ID=29558914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP27508 MEP27508A (en) | 2002-06-03 | 2003-05-20 | N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US7078428B2 (de) |
| EP (1) | EP1528923B1 (de) |
| JP (1) | JP4634793B2 (de) |
| KR (1) | KR101149771B1 (de) |
| CN (1) | CN1290833C (de) |
| AR (1) | AR039927A1 (de) |
| AT (1) | ATE324889T1 (de) |
| AU (1) | AU2003240677B2 (de) |
| BR (1) | BR0311556A (de) |
| CA (1) | CA2488373C (de) |
| CY (1) | CY1105115T1 (de) |
| DE (1) | DE60305042T2 (de) |
| DK (1) | DK1528923T3 (de) |
| EC (1) | ECSP045472A (de) |
| EG (1) | EG24784A (de) |
| ES (1) | ES2261939T3 (de) |
| FR (1) | FR2840302B1 (de) |
| HN (1) | HN2003000162A (de) |
| HR (1) | HRP20041151B1 (de) |
| IL (1) | IL165520A (de) |
| JO (1) | JO2357B1 (de) |
| MA (1) | MA27308A1 (de) |
| ME (1) | MEP27508A (de) |
| MX (1) | MXPA04011931A (de) |
| MY (1) | MY142502A (de) |
| NO (1) | NO329224B1 (de) |
| NZ (1) | NZ536953A (de) |
| OA (1) | OA12864A (de) |
| PA (1) | PA8574701A1 (de) |
| PE (1) | PE20040531A1 (de) |
| PL (1) | PL372188A1 (de) |
| PT (1) | PT1528923E (de) |
| RS (1) | RS51636B (de) |
| RU (1) | RU2318809C2 (de) |
| SI (1) | SI1528923T1 (de) |
| TN (1) | TNSN04237A1 (de) |
| TW (1) | TWI286545B (de) |
| UA (1) | UA81118C2 (de) |
| UY (1) | UY27835A1 (de) |
| WO (1) | WO2003101450A1 (de) |
| ZA (1) | ZA200409094B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7531569B2 (en) | 2003-12-02 | 2009-05-12 | Sanofi-Aventis Deutschland Gmbh | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives |
| DE10356717A1 (de) * | 2003-12-02 | 2005-07-07 | Aventis Pharma Deutschland Gmbh | Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten |
| KR100518184B1 (ko) * | 2003-12-27 | 2005-10-04 | 한국화학연구원 | 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물 |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| WO2007047646A2 (en) * | 2005-10-14 | 2007-04-26 | Janssen Pharmaceutica, N.V. | Substituted dihydro-isoindolones useful in treating kinase disorders |
| TW200812962A (en) * | 2006-07-12 | 2008-03-16 | Astrazeneca Ab | New compounds I/418 |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途 |
| US7790760B2 (en) | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| WO2012003147A1 (en) * | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| AR088320A1 (es) | 2011-10-14 | 2014-05-28 | Incyte Corp | Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt |
| CN103193794B (zh) * | 2013-04-12 | 2016-04-06 | 中国药科大学 | 一种异吲哚酮并异噁唑类稠环化合物及其合成方法 |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN106316922B (zh) * | 2016-08-17 | 2019-02-01 | 华东师范大学 | 一种含c-3全取代氧化吲哚衍生物及其合成方法和应用 |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN110664803B (zh) * | 2019-09-19 | 2023-08-29 | 中山大学 | 异吲哚酮类化合物在制备防治溶骨性疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| ATE157351T1 (de) * | 1993-02-20 | 1997-09-15 | Hoechst Ag | Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament, als inhibitoren des zellulären na+/h+-austauschs oder als diagnostikum sowie sie enthaltendes medikament |
| FR2735166B1 (fr) * | 1995-06-08 | 1997-08-29 | Aerospatiale | Procede de fabrication d'un panneau ou analogue a proprietes structurale et acoustique et panneau ainsi obtenu |
| DE19737224A1 (de) * | 1997-08-27 | 1999-03-18 | Hoechst Marion Roussel De Gmbh | Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen |
| DE19737463A1 (de) * | 1997-08-28 | 1999-03-04 | Hoechst Marion Roussel De Gmbh | Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden |
| DE19738604A1 (de) * | 1997-09-04 | 1999-03-11 | Hoechst Marion Roussel De Gmbh | Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe |
| YU46200A (sh) * | 1998-02-27 | 2003-02-28 | Pfizer Products Inc. | N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije |
| DE19859727A1 (de) * | 1998-12-23 | 2000-06-29 | Aventis Pharma Gmbh | Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung |
| US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| BR0110268A (pt) * | 2000-04-28 | 2003-12-30 | Pfizer Prod Inc | Inibidores de permutadores sódio-hidrogênio do tipo 1(nhe-1) |
| DE10046993A1 (de) * | 2000-09-22 | 2002-04-11 | Aventis Pharma Gmbh | Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament |
| EP1767525A1 (de) * | 2001-04-09 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Guanidinoverbindungen als Melanocortin-4-Rezeptor (MC4-R) Agonisten |
-
2002
- 2002-06-03 FR FR0206783A patent/FR2840302B1/fr not_active Expired - Fee Related
-
2003
- 2003-05-07 JO JO200351A patent/JO2357B1/en active
- 2003-05-20 PT PT03730076T patent/PT1528923E/pt unknown
- 2003-05-20 WO PCT/EP2003/005279 patent/WO2003101450A1/en not_active Ceased
- 2003-05-20 NZ NZ536953A patent/NZ536953A/en not_active IP Right Cessation
- 2003-05-20 AU AU2003240677A patent/AU2003240677B2/en not_active Ceased
- 2003-05-20 CN CNB038128500A patent/CN1290833C/zh not_active Expired - Fee Related
- 2003-05-20 JP JP2004508808A patent/JP4634793B2/ja not_active Expired - Fee Related
- 2003-05-20 EP EP20030730076 patent/EP1528923B1/de not_active Expired - Lifetime
- 2003-05-20 DK DK03730076T patent/DK1528923T3/da active
- 2003-05-20 MX MXPA04011931A patent/MXPA04011931A/es active IP Right Grant
- 2003-05-20 RU RU2004138789A patent/RU2318809C2/ru not_active IP Right Cessation
- 2003-05-20 ES ES03730076T patent/ES2261939T3/es not_active Expired - Lifetime
- 2003-05-20 DE DE2003605042 patent/DE60305042T2/de not_active Expired - Lifetime
- 2003-05-20 PL PL37218803A patent/PL372188A1/xx unknown
- 2003-05-20 BR BR0311556A patent/BR0311556A/pt not_active IP Right Cessation
- 2003-05-20 RS YUP104804 patent/RS51636B/sr unknown
- 2003-05-20 ME MEP27508 patent/MEP27508A/xx unknown
- 2003-05-20 KR KR1020047019619A patent/KR101149771B1/ko not_active Expired - Fee Related
- 2003-05-20 SI SI200330302T patent/SI1528923T1/sl unknown
- 2003-05-20 AT AT03730076T patent/ATE324889T1/de active
- 2003-05-20 UA UA20041211001A patent/UA81118C2/uk unknown
- 2003-05-20 OA OA1200400323A patent/OA12864A/en unknown
- 2003-05-20 CA CA 2488373 patent/CA2488373C/en not_active Expired - Fee Related
- 2003-05-20 HR HRP20041151AA patent/HRP20041151B1/hr not_active IP Right Cessation
- 2003-05-27 US US10/445,618 patent/US7078428B2/en not_active Expired - Lifetime
- 2003-05-29 PE PE2003000523A patent/PE20040531A1/es not_active Application Discontinuation
- 2003-05-30 TW TW92114642A patent/TWI286545B/zh not_active IP Right Cessation
- 2003-05-30 HN HN2003000162A patent/HN2003000162A/es unknown
- 2003-05-30 AR ARP030101923 patent/AR039927A1/es active IP Right Grant
- 2003-06-01 EG EG2003060521A patent/EG24784A/xx active
- 2003-06-02 PA PA8574701A patent/PA8574701A1/es unknown
- 2003-06-02 MY MYPI20032036 patent/MY142502A/en unknown
- 2003-06-03 UY UY27835A patent/UY27835A1/es unknown
-
2004
- 2004-11-10 ZA ZA2004/09094A patent/ZA200409094B/en unknown
- 2004-11-16 MA MA27951A patent/MA27308A1/fr unknown
- 2004-11-30 TN TNP2004000237A patent/TNSN04237A1/en unknown
- 2004-12-02 IL IL165520A patent/IL165520A/en not_active IP Right Cessation
- 2004-12-02 EC ECSP045472 patent/ECSP045472A/es unknown
- 2004-12-27 NO NO20045660A patent/NO329224B1/no not_active IP Right Cessation
-
2006
- 2006-03-01 US US11/365,319 patent/US7589117B2/en not_active Expired - Fee Related
- 2006-07-28 CY CY20061101057T patent/CY1105115T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20041151B1 (hr) | Derivati n-((3-okso-2,3-dihidro-1h-izoindol-1-il)-acetil)gvanidina kao nhe-1 inhibitori za lijeäśenje infarkta i angine pektoris | |
| Barreca et al. | Discovery of 2, 3-diaryl-1, 3-thiazolidin-4-ones as potent anti-HIV-1 agents | |
| BR0315405A (pt) | Compostos inibidores da integrase tricìclica pré-organizados | |
| KR950704304A (ko) | 이환식 헤테로환 함유 술폰아미드 및 술폰산 에스테르 유도체(bicyclic heterocyclic sulfonamide and sulfonic ester derivatives) | |
| NO990227D0 (no) | Heterocykliske forbindelser som farmas°ytika | |
| IL204594A (en) | Protein kinase inhibitors | |
| BR0014641A (pt) | Derivados de sulfonamida farmaceuticamente ativa, uso de um derivado de sulfonamida, uso de sulfonamidas, composto farmacêutico contendo pelo menos um derivado de sulfonamida e processo para preparação de um derivado de sulfonamida | |
| HUP0402307A2 (hu) | Kisméretű szerves molekulák a sejtproliferáció szabályozásához és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| BR0200982A (pt) | Compostos do ácido alfa-amino sulfonila, um processo para sua preparação e composições farmacêuticas compreendendo os mesmos | |
| HUP0301834A2 (hu) | Heterociklusos dihidropirimidin-származékok alkalmazása káliumcsatorna inhibitor hatású gyógyszerkészítmények elżállítására, valamint új származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| FI964218A7 (fi) | Yhdisteitä, joilla on verenpainetta alentavia, sydäntä suojaavia, verettömyyttä vastustavia ja rasvaa hajottavia ominaisuuksia | |
| KR970061865A (ko) | 신규 치환된 구아니딘 유도체, 그의 제조방법, 및 그의 약제학적 용도 | |
| EA200300864A1 (ru) | Триазолопиридины в качестве противовоспалительных средств | |
| MXPA05010210A (es) | Inhibidores no nucleosidos de transcriptasa inversa para tratar las enfermedades mediadas por el virus de la inmunodeficiencia humana (vih). | |
| ES350574A1 (es) | Procedimiento para la preparacion de 2,3,4,5-tetrahidro-1h-3-benzazepinas. | |
| CY1109882T1 (el) | Νεα αλατα ατορβαστατινης και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| EA200000792A2 (ru) | Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции | |
| HUP0000729A2 (hu) | Új amidszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
| MX393004B (es) | Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene. | |
| BRPI0810821A8 (pt) | Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos | |
| JP2024112835A5 (de) | ||
| RU94046369A (ru) | Новые стероиды на основе прегнана и фармацевтические композиции, их содержащие | |
| Ma et al. | Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors | |
| US5463122A (en) | Arylthio compounds | |
| MX2024015383A (es) | Compuesto de amina ciclica de azacicloalquilcarbonilo |